Skip to main content
. 2024 Jul 12;22(4):328–337. doi: 10.2450/BloodTransfus.667

Figure 2. Pre-apheresis CD34+ count, induction therapy group and CD34+ target.

Figure 2

Figure 2

Count of CD34+/μL in the two induction therapy groups: daratumumab-based (blue) and non daratumumab-based (red). A) Results from a ROC analysis considering the count of CD34+/μL and the ability to reach the set CD34+ target (target reached red, target not reached blue). B) The CD34+ count value of 54.49/μL appeared to be the most effective predictor of target achievement probability, with a sensitivity of 82% and specificity of 76%.